全文获取类型
收费全文 | 118771篇 |
免费 | 43831篇 |
国内免费 | 209篇 |
学科分类
医药卫生 | 162811篇 |
出版年
2023年 | 124篇 |
2022年 | 219篇 |
2021年 | 1805篇 |
2020年 | 6232篇 |
2019年 | 11638篇 |
2018年 | 11175篇 |
2017年 | 12403篇 |
2016年 | 11474篇 |
2015年 | 11426篇 |
2014年 | 11355篇 |
2013年 | 11620篇 |
2012年 | 10639篇 |
2011年 | 10648篇 |
2010年 | 9300篇 |
2009年 | 5835篇 |
2008年 | 6344篇 |
2007年 | 4761篇 |
2006年 | 4536篇 |
2005年 | 4271篇 |
2004年 | 4132篇 |
2003年 | 3802篇 |
2002年 | 3494篇 |
2001年 | 2655篇 |
2000年 | 1470篇 |
1999年 | 312篇 |
1998年 | 117篇 |
1997年 | 102篇 |
1996年 | 90篇 |
1995年 | 78篇 |
1994年 | 51篇 |
1993年 | 66篇 |
1992年 | 36篇 |
1991年 | 51篇 |
1990年 | 38篇 |
1989年 | 19篇 |
1988年 | 32篇 |
1987年 | 23篇 |
1986年 | 19篇 |
1985年 | 50篇 |
1984年 | 55篇 |
1983年 | 54篇 |
1982年 | 35篇 |
1981年 | 36篇 |
1980年 | 33篇 |
1979年 | 34篇 |
1978年 | 24篇 |
1977年 | 25篇 |
1976年 | 16篇 |
1975年 | 17篇 |
1973年 | 15篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
21.
22.
23.
24.
25.
Cost‐Effectiveness and Cost‐Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study
下载免费PDF全文
![点击此处可从《Neuromodulation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Furio Zucco MD Roberta Ciampichini MSc Angelo Lavano MD Amedeo Costantini MD Marisa De Rose MD Paolo Poli MD Gianpaolo Fortini MD Laura Demartini MD Enrico De Simone MD Valentino Menardo MD Piero Cisotto MD Mario Meglio MD Luciana Scalone PhD Lorenzo G. Mantovani DSc 《Neuromodulation》2015,18(4):266-276
26.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
27.
28.
29.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
30.